Accelerating glioblastoma therapeutics via venture philanthropy
Name
1-s2.0-S1359644621001550-main.pdf
Description
Published version
Size
288.47 KB
Format
Adobe PDF
Checksum (MD5)
63950600a5e7ecc6455b333d7cb066a2
Author(s)
Siah, Kien Wei
Xu, Qingyang
Tanner, Kirk
Futer, Olga
Frishkopf, John J
Lo, Andrew W
Date Issued
2021
Journal
Drug Discovery Today
Publisher
Elsevier BV
Citation
Siah, Kien Wei, Xu, Qingyang, Tanner, Kirk, Futer, Olga, Frishkopf, John J et al. 2021. "Accelerating glioblastoma therapeutics via venture philanthropy." Drug Discovery Today, 26 (7).
Version
Final published version
Abstract
Development of curative treatments for glioblastoma (GBM) has been stagnant in recent decades largely because of significant financial risks. A portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clinical trials for GBM. Using estimates from domain experts at the National Brain Tumor Society (NBTS), we analyze the performance of a portfolio of 20 assets being developed for GBM, diversified across different development phases and therapeutic mechanisms. We find that the portfolio generates a 14.9% expected annualized rate of return. By incorporating the adaptive trial platform GBM AGILE in our simulations, we show that at least one drug candidate in the portfolio will receive US Food and Drug Administration (FDA) approval with a probability of 79.0% in the next decade.
MIT Department
Sloan School of Management. Laboratory for Financial Engineering
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Massachusetts Institute of Technology. Operations Research Center
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.DRUDIS.2021.03.020
